Karamyan Vardan T, Speth Robert C
Department of Pharmacology and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States.
Regul Pept. 2007 Oct 4;143(1-3):15-27. doi: 10.1016/j.regpep.2007.03.006. Epub 2007 Mar 30.
The brain renin-angiotensin system continues to be enigmatic more than 40 years after the brain was first recognized to be a site of action of angiotensin II. This review focuses on the enzymatic pathways for the formation and degradation of the growing number of active angiotensins in the brain. A brief description and nomenclature of the peptidases involved in the processing of angiotensin peptides in the brain is given. Of primary interest is the array of enzymes that degrade radiolabeled angiotensins in receptor binding assays. This poses major challenges to studies of brain angiotensin receptors and it is debatable whether an accurate determination of brain angiotensin receptor binding kinetics has yet been made. The quandary facing the investigator of brain angiotensin receptors is the need to protect the radioligand from metabolic alteration while maintaining the characteristics of the receptors in situ. It is the tenet of this review that we have yet to fully understand the binding characteristics of brain angiotensin receptors and the extent of their distribution in the brain because of our inability to fully protect the angiotensins from metabolic alteration until equilibrium binding conditions can be attained.
自大脑首次被确认为血管紧张素II的作用部位以来,40多年过去了,大脑肾素-血管紧张素系统仍然充满谜团。本综述聚焦于大脑中越来越多活性血管紧张素的生成和降解的酶促途径。文中给出了参与大脑中血管紧张素肽加工的肽酶的简要描述和命名法。主要关注的是在受体结合试验中降解放射性标记血管紧张素的一系列酶。这给大脑血管紧张素受体的研究带来了重大挑战,对于是否已经准确测定大脑血管紧张素受体结合动力学仍存在争议。大脑血管紧张素受体研究者面临的困境是,需要在保持受体原位特征的同时,保护放射性配体不发生代谢改变。本综述的主旨是,由于我们无法在达到平衡结合条件之前完全保护血管紧张素不发生代谢改变,我们尚未充分了解大脑血管紧张素受体的结合特性及其在大脑中的分布范围。